Drug Profile
Telithromycin
Alternative Names: HMR-3647; Ketek; RU-647; RU-66647Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Antibacterials; Ketolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Gram-positive infections; Pharyngitis; Respiratory tract infections; Tonsillitis
- Discontinued Obstetric and gynaecological infections; Pelvic inflammatory disorders; Skin and soft tissue infections; Toxoplasmosis
Most Recent Events
- 30 Mar 2007 The EMEA has recommended restricted use of telithromycin in the treatment of bronchitis, sinusitis and tonsilitis/pharyngitis
- 13 Feb 2007 Withdrawn for Acute exacerbations of chronic bronchitis in USA (PO)
- 13 Feb 2007 Withdrawn for Acute sinusitis in USA (PO)